CRISPR and Type 1 Diabetes

CRISPR technology, a powerful gene-editing tool, holds significant promise for the treatment of Type 1 Diabetes (T1D). Researchers are exploring its potential to modify or replace defective genes responsible for autoimmune attacks on insulin-producing beta cells in the pancreas. One approach involves using CRISPR to correct genetic mutations in the immune system, potentially preventing the immune response that destroys these cells. Another promising application is the use of CRISPR to enhance stem cell therapy, enabling the generation of insulin-producing cells from pluripotent stem cells. While clinical applications are still in early stages, CRISPR's ability to precisely target and edit genes offers hope for a long-term cure, rather than just symptom management, in Type 1 Diabetes.

    CRISPR and Type 1 Diabetes Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in